2022 World Conference on Lung Cancer (ePosters)-EP16.03-026. Metastasis Sites and Genomic Alterations in Advanced Non Small Cell Lung Cancer: A Retrospective Study

Pdf Summary

A retrospective study was conducted to investigate the relationship between metastatic sites and genomic alterations in advanced non-small cell lung cancer (NSCLC) patients. The study included 33 patients with stage IV or recurrent NSCLC who underwent next-generation sequencing analysis. The main findings of the study are presented in Table 1, Table 2, and Figure 1.<br /><br />The results showed a trend between metastatic sites and specific genomic alterations. Brain metastases were associated with EGFR mutations, while pericardial metastases were associated with ALK rearrangements. Other significant findings included TP53 mutations in bone, pleura, distal lymph nodes, and regional lymph nodes; EGFR mutations in bone and pleura; KRAS mutations in bone, liver, and contralateral lung metastases; CDKN2A/B mutations in bone, pleura, distal lymph nodes, and pericardium; and SMAD4 mutations in bone and distal lymph nodes.<br /><br />The study highlights the need for a larger sample size to obtain a more comprehensive analysis and a better understanding of the biological behavior of NSCLC. Understanding the relationship between metastatic sites and genomic alterations can help in developing approaches to improve the prognosis of NSCLC.<br /><br />The findings of this study contribute to the existing knowledge about the molecular characteristics of NSCLC and support the importance of genomic profiling in guiding treatment decisions. Further research in this area may lead to the development of targeted therapies that are tailored to individual patients based on their specific genomic alterations.<br /><br />In conclusion, this retrospective study identified a relationship between metastatic sites and genomic alterations in advanced NSCLC patients. The findings suggest that specific genomic alterations may be associated with different metastatic sites, providing valuable insights for personalized treatment strategies. Further research is needed to validate these findings and explore the potential clinical implications.

Asset Subtitle

Juan Manuel Martínez-Valenciano

Meta Tag

Speaker Juan Manuel Martínez-Valenciano

Topic Tumour Biology and Biomarkers - Molecular Profiling and Targeted Therapies

Keywords

retrospective study

metastatic sites

genomic alterations

non-small cell lung cancer

NSCLC

next-generation sequencing analysis

EGFR mutations

ALK rearrangements

TP53 mutations

KRAS mutations